摘要
目的探讨贝那普利联合瑞格列奈治疗早期糖尿病肾病的疗效。方法运用随机数字表法将2011年6月。2012年6月在我院住院治疗的60例早期糖尿病肾病患者随机分为观察组和对照组,各30例,对照组患者给予盐酸贝那普利片治疗,观察组患者则加用瑞格列奈治疗,比较两组患者的临床疗效及治疗前后SCr的变化。结果观察组患者治疗总有效率(93.33%)明显高于对照组(70.00%),治疗前两组患者SCr比较差异无统计学意义(P〉0.05),治疗后观察组患者SCr降低较对照组更显著(P〈0.05)。结论贝那普利联合瑞格列奈治疗早期糖尿病肾病疗效确切,不良反应少,值得进一步推广。
Objective To investigate the efficacy of Benazepril plymouth united Repaglinide in treatment of early dia- betic nephropathy. Methods Used random number table from June 2011 to June 2012 in our hospital,60 eases early diabetic nephropathy were randomly divided into observation group and control group of the 30 eases,the control group were given Benazepril hydrochloride tablets treatment,the observation group were added with Repaglinide treat ment, clinical efficacy and SCr changes of two groups were compared before and after treatment. Results Total effi eiency of the observation group was 93.33% ,and was significantly higher than the control group (70.00%). Before treatment, difference of SCr between the two groups was not statistically signifieant(P 〉 0.05), after treatment,the SCr in the observation group reduced than the control group more significantly (P 〈 0.05). Conclusion The Be- nazepril plus Repaglinide treatment of early diabetic nephropathy has good efficacy, no adverse reactions, and Worthy of further promotion.
出处
《中国现代医生》
2013年第23期67-68,共2页
China Modern Doctor